Abstract
BackgroundHIV-negative, CD20-negative de novo diffuse large B-cell lymphoma (DLBCL) patients has rarely been reported. To elucidate the nature of this entity, we retrospectively reviewed the data of 1,456 consecutive de novo DLBCL patients who were treated at Sun Yat-Sen University Cancer Center between January 1999 and March 2011.MethodsThe pathologic characteristics of CD20-negative patients, clinical features, response to initial treatment, and outcomes of 28 patients with available clinical data (n = 21) were reviewed. Then, a matched case-control (1:3) analysis was performed to compare patients with CD20-negative and -positive DLBCL.ResultsThe median age of the 28 CD20-negative DLBCL patients was 48 years, with a male-female ratio of 20:8. Seventeen of 22 (77.3%) CD20-negative DLBCL cases were of the non-germinal centre B-cell (non-GCB) subtype. High Ki67 expression (≥80%), an index of cell proliferation, was demonstrated in 17 of 24 (70.8%) cases. Extranodal involvement (≥ 1 site) was observed in 76.2% of the patients. Following initial therapy, 9 of 21 (42.9%) cases achieved complete remission, 4 (19%) achieved partial remission, 1 (4.8%) had stable disease, and 7 (33.3%) had disease progression. The median overall survival was 23 months. The 3-year progression-free survival (PFS) and overall survival (OS) rates were 30.5% and 35%, respectively. A matched case-control analysis showed that patients with CD20-negative and -positive DLBCL did not exhibit a statistically significant difference with respect to the main clinical characteristics (except extranodal involvement), whereas the patients with CD20-positive DLBCL had a better survival outcome with 3-year PFS (P = 0.008) and OS (P = 0.008) rates of 52% and 74.1%, respectively.ConclusionsThis study suggests that HIV-negative, CD20-negative de novo DLBCL patients have a higher proportion of non-GCB subtype, a higher proliferation index, more frequent extranodal involvement, a poorer response, and a poorer prognosis to conventional treatment compared to patients with CD20-positive DLBCL. Further studies are warranted to investigate new target and optimal therapy of CD20-negative de novo DLBCL.
Highlights
HIV-negative, CD20-negative de novo diffuse large B-cell lymphoma (DLBCL) patients has rarely been reported
The following clinicopathologic variables associated with survival in common DLBCL were dichotomized to facilitate univariate analysis for survival of HIV-negative, CD20-negative de novo DLBCL patients, which were compared using the Kaplan-Meier method and log-rank test: age (>60 years vs. ≤ 60 years), Eastern Cooperative Oncology Group (ECOG) performance status (PS; >1 vs. ≤ 1), stage, bulky (≥ 7 cm vs. < 7 cm), serum lactate dehydrogenase (LDH), extranodal involvement (≥ 2 vs. < 2), international prognosis index (IPI) (0-1 vs. 2-3), Ki-67 (≥ 80% vs.
Histologic and immunohistochemical features, and In situ hybridization (ISH) and Fluorescent in situ hybridization (FISH) studies We reviewed the pathologic data of 1,456 consecutive patients with de novo DLBCL diagnosed at Sun Yat-Sen University Cancer Center between January 1999 and March 2011
Summary
HIV-negative, CD20-negative de novo diffuse large B-cell lymphoma (DLBCL) patients has rarely been reported. Limited studies with a large series of cases have focused on the clinical and pathologic features of HIV-negative, CD20-negative de novo DLBCL patients [9,10,11,12,13,14]. To shed light on the nature of the entity, we conducted a matched case-control analysis to compare the clinicopathologic characteristics and clinical outcome of HIVnegative, CD20-negative DLBCL and -positive DLBCL patients at a single institution. This is the first matched case-control analysis to investigate HIV-negative, CD20negative DLBCL patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
